Article
AI-Driven Design of Nanobinders Targeting the TSLPR Heterodimer Interface to Suppress Type 2 Inflammatory Signaling
2026-07-22
Abstract excerpt
Aberrant thymic stromal lymphopoietin (TSLP) signaling is a central driver of type 2 inflammatory diseases, yet the only approved TSLP-targeted therapy is a 150 kDa monoclonal antibody whose bulky format limits tissue penetration and precludes inhaled delivery. Here, we report an AI-driven framework for designing ultra-compact de novo nanobinders that suppress TSLP signaling by sterically disrupting assembly of t...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 918f4cf9-8b7d-5103-b83d-f66142da0c2e
- DOI
- 10.64898/2026.07.20.739581
